This approach has shown success in displaying carcinoembryonic antigen (CEA) and HER2 on EVs for enhancing vaccine development [30] and recently to target HER2+ breast cancer cells with EVs displaying scvHER2 antibodies to deliver mRNA prodrugs for anti-cancer activity [31]. Here, ERBB2 is linked to breast cancer.